Chronic lymphocytic leukemia with MDM2 amplification as an alternative pathway to TP53 dysfunction

被引：0
|
作者：
Hunter, Sally [1 ,6 ]
Ryland, Georgina [1 ,2 ,6 ]
Pang, Jia-Min [1 ,6 ]
Ninkovic, Slavisa [3 ]
Dun, Karen [3 ,4 ]
Seymour, John F. [5 ,7 ]
Blombery, Piers [1 ,2 ,5 ,6 ]
机构：
[1] Peter MacCallum Canc Ctr, Dept Pathol, Melbourne, Vic, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Australia
[3] St Vincents Hosp Melbourne, Victorian Canc Cytogenet Serv, Melbourne, Vic, Australia
[4] St Vincents Hosp Melbourne, Dept Haematol, Melbourne, Vic, Australia
[5] Peter MacCallum Canc Ctr, Clin Haematol, Melbourne, Vic, Australia
[6] Royal Melbourne Hosp, Melbourne, Vic, Australia
[7] Univ Melbourne, Fac Med Dent & Hlth Sci, Melbourne, Vic, Australia
来源：
LEUKEMIA & LYMPHOMA | 2024年 / 65卷 / 14期
关键词：
D O I：
10.1080/10428194.2024.2398659
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2215 / 2218
页数：4
相关论文
共 50 条
  • [1] Infrequent mutations of the TP53 gene and no amplification of the MDM2 gene in hepatoblastomas
    Ohnishi, H
    Kawamura, M
    Hanada, R
    Kaneko, Y
    Tsunoda, Y
    Hongo, T
    Bessho, F
    Yokomori, K
    Hayashi, Y
    GENES CHROMOSOMES & CANCER, 1996, 15 (03): : 187 - 190
  • [2] TP53 Aberrations in Chronic Lymphocytic Leukemia
    Trbusek, Martin
    Malcikova, Jitka
    ADVANCES IN CHRONIC LYMPHOCYTIC LEUKEMIA, 2013, 792 : 109 - 131
  • [3] Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations
    Ahn, Inhye E.
    Tian, Xin
    Wiestner, Adrian
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (05): : 498 - 500
  • [4] TP53 Mutation and Survival in Chronic Lymphocytic Leukemia
    Zenz, Thorsten
    Eichhorst, Barbara
    Busch, Raymonde
    Denzel, Tina
    Haebe, Sonja
    Winkler, Dirk
    Buehler, Andreas
    Edelmann, Jennifer
    Bergmann, Manuela
    Hopfinger, Georg
    Hensel, Manfred
    Hallek, Michael
    Doehner, Hartmut
    Stilgenbauer, Stephan
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (29) : 4473 - 4479
  • [5] p53 dysfunction in B-cell chronic lymphocytic leukemia:: inactivation of ATM as an alternative to TP53 mutation
    Pettitt, AR
    Sherrington, PD
    Stewart, G
    Cawley, JC
    Taylor, AMR
    Stankovic, T
    BLOOD, 2001, 98 (03) : 814 - 822
  • [6] TP53 mutations and mdm2 protein overexpression in cholangiocarcinomas
    Della Torre, G
    Pasquini, G
    Pilotti, S
    Alasio, L
    Civelli, E
    Cozzi, G
    Milella, M
    Salvetti, M
    Pierotti, MA
    Severini, A
    DIAGNOSTIC MOLECULAR PATHOLOGY, 2000, 9 (01) : 41 - 46
  • [7] Activating TP53 by Dual Inhibition of MDMX and MDM2
    Steidl, Ulrich G.
    BLOOD, 2019, 134
  • [8] Genetic variability profiling of the p53 signaling pathway in chronic lymphocytic leukemia. Individual and combined analysis of TP53, MDM2 and NQO1 gene variants
    Fontecha, Maria Belen
    Anadon, Maria Del Rosario
    Guzman, Veronica Mercado
    Stanganelli, Carmen
    Galvano, Camila
    Tosin, Fernanda
    Bordone, Javier
    Bezares, Raimundo
    Rodriguez, Cecilia
    Heller, Viviana
    Slavutsky, Irma
    Fundia, Ariela Freya
    ANNALS OF HEMATOLOGY, 2024, 103 (12) : 5703 - 5712
  • [9] Analysis of MDM2 and TP53 genes in canine liposarcoma
    Muscatello, Luisa Vera
    de Biase, Dario
    Maloberti, Thais
    di Oto, Enrico
    Tallini, Giovanni
    Pellegrino, Valeria
    Bacci, Barbara
    Roccabianca, Paola
    Lepri, Elvio
    Crippa, Luca
    Avallone, Giancarlo
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [10] The TP53 Codon72 Polymorphism Is Associated with TP53 Mutations in Chronic Lymphocytic Leukemia
    Grossmann, Vera
    Artusi, Valentina
    Schnittger, Susanne
    Dicker, Frank
    Jeromin, Sabine
    Boeck, Lucia
    Haferlach, Torsten
    Haferlach, Claudia
    Kern, Wolfgang
    Kohlmann, Alexander
    BLOOD, 2011, 118 (21) : 778 - 778
12345